SANA

Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company founded in 2018 and headquartered in Seattle, Washington. Originally incorporated as FD Therapeutics, Inc., the company changed its name to Sana Biotechnology in September 2018 before going public in February 2021. Sana focuses on developing engineered cells as medicines, representing a cutting-edge approach in biotechnology where living cells are modified to treat diseases rather than using traditional small molecule drugs or biologics.